Turn left or turn right? Lessons from the management of intraoperative cardiac arrest due to Type I Kounis syndrome: a case report Authors: Yuanyuan Rong, Zhaolei Tian, Tao Hu, Haishan Feng, Lei Wang, Yong-be Zhao, Jianfeng Fu, Aiyu Zhang, Huaqin Liu Published: 2026 ABSTRACT Kounis syndrome (KS), also known as allergic angina syndrome, is a potentially life-threatening perioperative condition that may be underrecognized under general anesthesia. Management is challenging because anaphylaxis and acute coronary events can occur concurrently and progress to cardiac arrest. We report a 70-year-old man undergoing elective left thoracoscopic lobectomy under general anesthesia. During the procedure, he developed abrupt hypotension and ST-segment elevation followed by ventricular fibrillation (VF). Cardiopulmonary resuscitation (CPR) was initiated, and 1 mg intravenous (IV) epinephrine was administered. The first defibrillation attempt failed to restore an organized rhythm. Marked erythema on both upper extremities was noted and intraoperative anaphylaxis was suspected. Despite anti-anaphylaxis treatment and two additional defibrillation attempts, there was no response. A cardiologist was consulted and internal defibrillation was initiated. After opening the pericardium, papaverine was administered. Sinus rhythm was obtained after the fourth defibrillation, with a total resuscitation time of 29 min. The patient was transferred to the intensive care unit (ICU) and was ultimately diagnosed with Type I Kounis syndrome. He was discharged without complications. This case suggests that in patients without underlying coronary artery disease, reversible coronary vasospasm may represent a pre-dominant pathophysiological mechanism in Type I Kounis syndrome. Early consideration of coronary vasodilator therapy, alongside standard anaphylaxis management, may therefore be warranted in selected perioperative settings. Background KS is a potentially life-threatening perioperative entity that may be underrecognized, particularly under general anesthesia (1–3). Its management is challenging because anaphylaxis and acute coronary events can occur simultaneously and may progress to cardiac arrest requiring CPR (4). Because typical ischemic symptoms cannot be reported under anesthesia, recognition often relies on hemodynamic instability and dynamic ECG changes, which may delay diagnosis and treatment. We report a perioperative case of Type I KS under general anesthesia to highlight key diagnostic and management considerations. Case description A 70-year-old man was electively admitted for left video-assisted thoracoscopic surgery in the right lateral decubitus position. He had no medical history of hypertension, diabetes, or coronary artery disease, and no known drug or food allergies. At 2:40 p.m., baseline vital signs were as follows: non-invasive blood pressure (NIBP) 150/62 mmHg, SpO2 97%, and heart rate (HR) 62 beats/min. General anesthesia was induced with remimazolam 15 mg, sufentanil 30 μg, and cisatracurium 12 mg. Tracheal intubation was performed uneventfully. Anesthesia was maintained with a continuous remifentanil infusion and sevoflurane 1.5%−2.0%. Shortly after induction, localized papules appeared on the right upper limb, accompanied by bradycardia (HR 43 beats/min) and hypotension (BP 90/52 mmHg). An intravenous bolus of ephedrine was administered, after which BP increased to 112/50 mmHg and HR to 68 beats/min. At 4:22 p.m., the patient developed sudden ST-segment elevation with marked hypotension. A norepinephrine bolus followed by continuous infusion was administered. Telemetry showed resolution of the ST-segment changes as BP increased to 140/72 mmHg. At 4:30 p.m., VF occurred, followed by cardiac arrest. The inspired oxygen fraction was increased to 100%, and CPR was initiated. The initial defibrillation attempt was unsuccessful. Generalized rash was noted after the sterile drapes were removed, and intraoperative anaphylaxis was suspected; antihistamines and corticosteroids were administered immediately. Despite IV epinephrine, lidocaine, and amiodarone, subsequent defibrillation attempts at 4:40 p.m. were unsuccessful. At 4:48 p.m., an experienced cardiac surgeon was consulted, the pericardium was opened, and internal defibrillation was performed, but no organized rhythm was restored. At 4:55 p.m., papaverine 30 mg was administered intravenously, and an additional 30 mg (diluted in 10 ml normal saline) was applied topically to the cardiac surface. After the fourth defibrillation at 4:59 p.m., sinus rhythm was restored, although the HR was approximately 30 beats/min. Atropine 5 mg was administered intravenously, and the HR increased to 70–80 beats/min. Given the marked response, an additional 30 mg of papaverine in 500 ml of normal saline was administered as a continuous IV infusion. By 5:28 p.m., vital signs had stabilized. The operation was completed, and the patient was transferred to ICU at 6:00 p.m. On post-operative day (POD) 4, coronary angiography revealed no significant stenosis in the major coronary arteries. The endotracheal tube was removed on POD 8, and the patient was able to ambulate independently on POD 15. Post-operative troponin levels over time are shown in Figure 1. The patient was discharged on POD 29 without complications (Table 1). Post-operative changes in troponin levels. The normal reference range for troponin is 0–0.034 μg/L. Table 1Chronological timeline of perioperative events, physiologic changes, interventions, and clinical reasoning.TimeClinical findingsMonitoring changesInterventionsClinical reasoning2:40 p.m.Induction of anesthesiaNIBP 150/62 mmHg; HR 62 bpmRemimazolam; sufentanil; cisatracuriumBaseline statusA few minutes after inductionLocalized papules on the right upper limbHR 43 bpm; BP 90/52 mmHgIV ephedrine bolusInitial consideration: allergic/anesthetic-related reaction4:22 p.m.Sudden ST-segment elevationMarked hypotensionNorepinephrine bolus and infusionConsideration of coronary involvement4:30 p.m.Ventricular fibrillation; cardiac arrestNo effective circulation on ECG monitoringCPR; IV epinephrine 1 mgResuscitation according to guidelines4:40 p.m.Defibrillation unsuccessfulPersistent VFAnti-allergic therapy; repeat defibrillationSuspected allergy-related mechanism4:48 p.m.Pericardium opened; cardiac massage and internal defibrillation performedNo return of spontaneous circulation (ROSC)Cardiac surgical team involvedRefractory resuscitation4:55 p.m.Ongoing cardiac massage and defibrillationNo ROSCPapaverine (30 mg IV; 30 mg topical to the cardiac surface)Coronary vasospasm strongly suspected4:59 p.m.Sinus rhythm restored after the 4 th defibrillationHR ~30 bpmAtropine 5 mgRelief of vasospasm considered~5:00 p.m.Post-ROSC bradycardiaHR increased to 70–80 bpmContinuous IV papaverine infusion (30 mg diluted in 500 ml normal saline)Maintain coronary vasodilation5:28 p.m.Hemodynamics stabilizedVital signs stableOngoing monitoring/supportive careStabilization achieved6:00 p.m.Post-operative transferVital signs stableTransferred to ICU after completion of surgeryPost-resuscitation managementPOD 4Coronary angiographyNo significant stenosis—Type I Kounis syndrome confirmedPOD 8ExtubationStableEndotracheal tube removedRespiratory recoveryPOD 15MobilizationClinically stableAmbulated independentlyFunctional recoveryPOD 29DischargeNo complicationsDischarged without complicationsFavorable outcome Chronological timeline of perioperative events, physiologic changes, interventions, and clinical reasoning. Discussion KS refers to acute coronary events triggered by the massive release of inflammatory mediators during an allergic or hypersensitivity reaction. Based on the underlying coronary status, KS is generally classified into three variants: Type I occurs in patients with angiographically normal coronary arteries and is characterized pre-dominantly by reversible coronary vasospasm; Type II occurs in patients with pre-existing atherosclerotic disease and involves plaque disruption and/or thrombosis triggered by an allergic reaction; and Type III is associated with stent thrombosis (5–7). In our patient, post-operative coronary angiography revealed no significant stenosis or evidence of plaque rupture, which is more consistent with Type I Kounis syndrome. The perioperative setting is a high-risk context for KS because multiple potential sensitizing exposures may occur within a short time frame. Common triggers include anesthetic-related agents (e.g., remimazolam, sufentanil, cisatracurium), perioperative antibiotics, and colloid solutions. These exposures may activate mast cells through IgE-dependent or non–IgE-dependent pathways and initiate an inflammatory cascade. In this case, localized papules and transient hypotension developed shortly after induction of anesthesia, suggesting that a hypersensitivity response may have started early. Because multiple potential allergens are often present perioperatively and no allergen-specific testing was performed, a single culprit cannot be identified, and a multifactorial trigger cannot be excluded. Under general anesthesia, patients cannot report chest pain or other typical ischemic symptoms. Therefore, perioperative recognition of KS relies largely on hemodynamic instability and dynamic intraoperative electrocardiographic changes (5). In our patient, ST-segment elevation and malignant arrhythmias developed after the allergic manifestations appeared, suggesting coronary involvement. Prior reports have noted that some cases present initially only with hypotension or rash and are recognized later when ST changes emerge, leading to delayed diagnosis (2). KS has been reported more frequently in men aged 40–80 years, and symptoms typically occur shortly after exposure to the triggering agent (4, 8). Accordingly, when dynamic ECG changes or worsening hemodynamic instability occur in the setting of an allergic reaction, clinicians should maintain a high index of suspicion for coronary involvement. From a differential diagnosis standpoint, the first step is to distinguish perioperative anaphylaxis from KS. Perioperative allergic reactions commonly present with generalized features such as rash, hypotension, and bronchospasm, and they often improve rapidly with anti-allergic treatment, without persistent evidence of myocardial ischemia. However, when dynamic ST-segment changes, malignant arrhythmias, or poor response to standard anti-allergic management accompany an allergic presentation, coronary involvement should be strongly considered. Other acute coronary entities should also be excluded. Primary acute coronary syndrome is an important consideration; although our patient developed ST elevation and VF, post-operative coronary angiography showed no significant stenosis or plaque rupture, and there was no history of atherosclerotic disease, arguing against a typical plaque-rupture myocardial infarction. Takotsubo syndrome can also present with stress-related ST changes and arrhythmias, but it is usually accompanied by characteristic apical ballooning and reversible left ventricular dysfunction, for which supportive imaging evidence was lacking in this case. Isolated coronary spasm may mimic these findings; however, in our patient, systemic allergic manifestations and hemodynamic fluctuations preceded the coronary event, and the response to the vasodilator papaverine was pronounced, making an inflammatory mediator–driven coronary smooth muscle spasm more plausible. Considering the temporal sequence, exclusion by imaging, and treatment response, the diagnosis in this case favors Type I Kounis syndrome. Key features distinguishing perioperative anaphylaxis from KS in anesthetized patients are summarized in Table 2. Table 2Key differential features between perioperative anaphylaxis and Kounis syndrome (under general anesthesia).DomainAnaphylaxisKounis syndromeCore mechanismSystemic hypersensitivity reaction with peripheral vasodilation and capillary leakAllergic reaction with concomitant coronary involvement (vasospasm and/or plaque disruption)Common perioperative triggersAnesthetic agents, perioperative antibiotics, colloids, blood productsSimilar perioperative triggers (often drug-related)Typical onsetUsually within minutes after exposureAlso usually within minutes after exposureCutaneous manifestationsCommon (rash, flushing)Common (often present in Type I)HypotensionCommonCommonBronchospasmMay occurMay occurDynamic ST-segment changesUsually absentCommon (ST elevation or depression)Malignant arrhythmiasUncommonMay occur (VT, VF)Cardiac biomarkersUsually normalMay be elevatedCoronary angiographyNormalType I: normal; Type II: plaques and/or thrombosis may be presentResponse to epinephrineUsually effectiveMay be suboptimal and/or worsen ischemiaResponse to vasodilatorsNo clear benefitOften improves (nitrates, calcium channel blockers, papaverine)Key perioperative clues under general anesthesiaPredominantly hypotension and/or bronchospasmAllergic manifestations plus dynamic ECG changes or otherwise unexplained arrhythmiasPerioperative “red flags”Hypotension with stable ECGAllergic manifestations with ST changes or poor response to resuscitationKey distinguishing pointNo evidence of coronary ischemiaEvidence of coronary ischemia and/or vasospasm Key differential features between perioperative anaphylaxis and Kounis syndrome (under general anesthesia). Therapeutically, determining the priority between treating an allergic reaction and managing an acute coronary process is a major clinical challenge in the perioperative setting. Because KS often involves concurrent hypersensitivity and coronary involvement, clinicians must dynamically balance these two pathophysiologic processes. In our patient, ST-segment elevation rapidly progressed to VF, and CPR was initiated immediately in accordance with current resuscitation guidelines, including epinephrine administration (9). However, in suspected Type I KS, epinephrine may improve allergy-related circulatory compromise yet also increase myocardial oxygen demand and enhance coronary vasoconstriction, thereby precipitating or worsening myocardial ischemia and vasospasm (10). In this case, when conventional resuscitative measures had limited effect, return of spontaneous rhythm occurred after intravenous and topical papaverine, suggesting that reversible coronary vasospasm may have played a dominant role in the circulatory collapse, consistent with Shibuya et al.'s (11) report of spastic contraction of coronary smooth muscle during KS events. From a clinical perspective, sinus rhythm was restored following the administration of papaverine. This temporal association supports the hypothesis of coronary vasospasm to some extent; however, given the nature of a single-case observation, a definitive causal relationship cannot be established. Accordingly, for life-threatening allergic reactions, epinephrine should remain a first-line agent as recommended by current guidelines (12). Nevertheless, when clinical clues suggest concomitant coronary vasospasm, the route and dose of epinephrine should be reassessed cautiously under close monitoring, and coronary vasodilator therapy should be initiated early in parallel. Nitrates or calcium channel blockers (CCB) may help relieve functional flow limitation, and papaverine can be considered as a vasodilator option. Papaverine can be considered as a vasodilator option due to its direct smooth muscle relaxation effect, which may help relieve coronary vasospasm in Type I Kounis syndrome. However, we acknowledge that systemic vasodilation induced by papaverine may potentially worsen hypotension, particularly in hemodynamically unstable patients. In our case, papaverine was administered under close hemodynamic monitoring, and the decision was based on a risk–benefit consideration, prioritizing the reversal of suspected coronary vasospasm after conventional resuscitative measures had failed. Meanwhile, antihistamines and corticosteroids may attenuate the inflammatory cascade and reduce the risk of sustained vasoconstriction. Based on these mechanistic considerations and our clinical observations, we drafted a perioperative management approach for suspected Type I KS (Table 3) to support clinical decision-making. Table 3Suggested perioperative management considerations for suspected Type I Kounis syndrome.ItemPhase 1: allergy-dominantPhase 2: overlap (allergy + coronary involvement)Phase 3: vasospasm-dominantPredominant pathophysiologyMast cell activation; mediator surgeMediator-driven coronary constriction; endothelial dysfunctionSevere reversible coronary vasospasm; functional flow limitationTypical featuresRash; hypotension; bronchospasm; no persistent STDynamic ST; hemodynamic instability; arrhythmia tendencyPersistent ST; VT/VF; poor response to resuscitationPriorityAnaphylaxis: high Vasodilation: lowAnaphylaxis: mod–high Vasodilation: mod–highAnaphylaxis: maintenance Vasodilation: highAnaphylaxis managementFluids; H1 antihistamine; H2 blocker; corticosteroid; epinephrine (per guideline)Continue antihistamine + corticosteroidMaintain basic anti-allergic therapyCoronary vasodilationNot prioritizedNitrates; CCB (diltiazem/verapamil); nicorandil; papaverinePrioritize nitrates; CCB; papaverine (IV/topical); nicorandil (if needed)Epinephrine strategyStandard per guidelineCautious; balance α/β effectsHighly cautious; avoid excessive α-mediated vasoconstrictionKey focusControl systemic allergy; stabilize circulationControl allergy + improve coronary perfusionRelieve vasospasm; restore flow; limit ongoing ischemia Suggested perioperative management considerations for suspected Type I Kounis syndrome. Mechanistically, the central pathological basis of Type I KS is excessive mast cell activation (6). Following initiation of an allergic response, mast cell degranulation releases histamine, leukotrienes, platelet-activating factor, and multiple inflammatory cytokines. These mediators can directly provoke coronary smooth muscle contraction and may further amplify vasoconstriction by impairing endothelium-dependent vasodilation (13). Emerging evidence suggests a direct relationship between mast cell activation and endothelial dysfunction. In patients with systemic mastocytosis, serum tryptase levels have been shown to correlate inversely with flow-mediated dilation, indicating that greater mast cell activation is associated with poorer endothelium-dependent vasodilatory function (14). This finding provides biological plausibility for the combination of mediator-driven coronary vasospasm and endothelial dysfunction in Type I KS. In this context, coronary spasm is unlikely to reflect a purely reflexive smooth muscle response, but rather an interaction among inflammation, endothelium, and vascular smooth muscle. Overall, in perioperative patients with suspected KS, management should shift from a single-disease framework to an integrated, mechanism-oriented strategy. Dynamic assessment of the pre-dominant pathophysiology and timely adjustment of treatment priorities are essential to enable individualized decision-making. Importantly, this case differs from previously reported case series by providing a detailed perioperative and anesthesia-oriented perspective. In contrast to prior reports that primarily describe clinical outcomes, our case emphasizes real-time decision-making in a high-stakes intraoperative setting, where anaphylaxis and coronary ischemia must be addressed simultaneously. This highlights the complexity of competing priorities and offers practical insights for anesthesiologists managing similar scenarios. Conclusion In summary, this case suggests that in patients without underlying coronary artery disease, reversible coronary vasospasm may represent a pre-dominant pathophysiological mechanism in Type I Kounis syndrome. Early consideration of coronary vasodilator therapy, alongside standard anaphylaxis management, may therefore be warranted in selected perioperative settings. This case also underscores the importance of an integrated, mechanism-based approach in perioperative critical events, rather than relying solely on standard single-pathway management strategies.